MA37383A1 - Compose heterobicycliques comme inhibiteurs de la beta lactamase - Google Patents

Compose heterobicycliques comme inhibiteurs de la beta lactamase

Info

Publication number
MA37383A1
MA37383A1 MA37383A MA37383A MA37383A1 MA 37383 A1 MA37383 A1 MA 37383A1 MA 37383 A MA37383 A MA 37383A MA 37383 A MA37383 A MA 37383A MA 37383 A1 MA37383 A1 MA 37383A1
Authority
MA
Morocco
Prior art keywords
inhibitors
beta
compounds
beta lactamase
pharmaceutically acceptable
Prior art date
Application number
MA37383A
Other languages
English (en)
Inventor
Neil Bifulco
Helen Mcguire
Shanta Bist
Liang Zhao
Ye Wu
Hoan Huynh
Hui Xiong
Janelle Comita-Prevoir
Daemian Dussault
Bolin Geng
Brendan Chen
Thomas Durand-Reville
Satenig Guler
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA37383A1 publication Critical patent/MA37383A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés qui sont des inhibiteurs de la bêta-lactamase. Ces composés et leurs sels acceptables sur le plan pharmaceutique sont utiles en combinaison avec des antibiotiques de type bêta-lactame, ou seuls, pour le traitement d'infections bactériennes, y compris d'infections provoquées par des organismes résistant aux médicaments, y compris des organismes multi-résistants. La présente invention comprend des composés de formule (ia), ou un sel acceptable sur le plan pharmaceutique desdits composés, les valeurs de r1, r2, r3 et r4 étant telles que définies dans la description.
MA37383A 2012-04-02 2013-04-02 Compose heterobicycliques comme inhibiteurs de la beta lactamase MA37383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618993P 2012-04-02 2012-04-02
PCT/GB2013/050869 WO2013150296A1 (fr) 2012-04-02 2013-04-02 Composés hétérobicycliques comme inhibiteurs de la bêta-lactamase

Publications (1)

Publication Number Publication Date
MA37383A1 true MA37383A1 (fr) 2016-06-30

Family

ID=48083562

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37383A MA37383A1 (fr) 2012-04-02 2013-04-02 Compose heterobicycliques comme inhibiteurs de la beta lactamase

Country Status (41)

Country Link
US (2) US9309245B2 (fr)
EP (1) EP2834239B1 (fr)
JP (1) JP6122484B2 (fr)
KR (1) KR102042867B1 (fr)
CN (1) CN104364254B (fr)
AP (1) AP2014007980A0 (fr)
AR (1) AR090539A1 (fr)
AU (1) AU2013245399B2 (fr)
BR (1) BR112014024279B1 (fr)
CA (1) CA2866467C (fr)
CL (1) CL2014002589A1 (fr)
CO (1) CO7071137A2 (fr)
CR (1) CR20140428A (fr)
CY (1) CY1120269T1 (fr)
DK (1) DK2834239T3 (fr)
DO (1) DOP2014000212A (fr)
ES (1) ES2663416T3 (fr)
HR (1) HRP20180450T1 (fr)
HU (1) HUE036722T2 (fr)
IL (1) IL234660A (fr)
IN (1) IN2014MN01882A (fr)
LT (1) LT2834239T (fr)
MA (1) MA37383A1 (fr)
ME (1) ME03031B (fr)
MX (1) MX354627B (fr)
MY (1) MY176969A (fr)
NO (1) NO2935238T3 (fr)
NZ (1) NZ630259A (fr)
PE (1) PE20142403A1 (fr)
PH (1) PH12014502224B1 (fr)
PL (1) PL2834239T3 (fr)
PT (1) PT2834239T (fr)
RS (1) RS56966B1 (fr)
RU (1) RU2645678C2 (fr)
SG (1) SG11201405965RA (fr)
SI (1) SI2834239T1 (fr)
SM (1) SMT201800142T1 (fr)
TN (1) TN2014000417A1 (fr)
TW (1) TWI597281B (fr)
UY (1) UY34723A (fr)
WO (1) WO2013150296A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
KR102542392B1 (ko) 2014-11-17 2023-06-09 엔타시스 테라퓨틱스 리미티드 내성 박테리아 감염의 치료를 위한 배합물 치료제
BR112017020796A2 (pt) * 2015-03-31 2018-06-26 Mutabilis compostos, composição farmacêutica e kit
TW201639853A (zh) 2015-03-31 2016-11-16 木塔比利斯公司 雜環化合物及其於預防或治療細菌感染之用途
EP3075733A1 (fr) * 2015-03-31 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
EP3075381A1 (fr) * 2015-04-03 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
CN107438614B (zh) * 2015-04-03 2020-01-31 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3091018A1 (fr) * 2015-05-07 2016-11-09 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
CA2983674A1 (fr) * 2015-05-07 2016-11-10 Mutabilis Composes heterocycliques et leur utilisation dans la prevention ou le traitement d'infections bacteriennes
CA3000087A1 (fr) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions et methodes pour inhiber la beta-lactamase
EP3184529A1 (fr) 2015-12-23 2017-06-28 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
WO2017203266A1 (fr) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Polythérapie pour le traitement d'infections bactériennes résistantes
CN114591223B (zh) * 2016-09-16 2025-01-24 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3300736B1 (fr) 2016-09-30 2021-05-05 Mutabilis Composition comprenant un composé antibiotique et un composé hétérocyclique et leur utilisation pour prévenir ou traiter des infections bactériennes
EP3301094A1 (fr) * 2016-09-30 2018-04-04 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
NZ758200A (en) * 2017-05-08 2025-12-19 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN112165936B (zh) 2018-05-14 2023-11-28 国立大学法人东海国立大学机构 β-内酰胺酶抑制剂
SG11202101255UA (en) * 2018-08-09 2021-03-30 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3608318A1 (fr) * 2018-08-09 2020-02-12 Antabio SAS Derives de diaazabicyclooctanone comme antibiotiques
RU2739761C2 (ru) * 2018-09-27 2020-12-28 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения n-алкил-n-{ [3-алкил-3,8-диазабицикло[3.2.1]окта-1(7),5-диен-8-ил]метил} аминов и их применение в качестве средств с антимикробной активностью
CN111196808B (zh) * 2018-11-16 2022-10-18 南京圣和药业股份有限公司 二氮杂双环类化合物及其应用
CN110615790A (zh) * 2019-10-24 2019-12-27 北京融英医药科技有限公司 一种利格列汀制备工艺的改进方法
US20220194791A1 (en) * 2020-12-22 2022-06-23 Tokyo Ohka Kogyo Co., Ltd. Method for producing aqueous solution of purified orthoperiodic acid, method for producing semiconductor device, and aqueous solution of orthoperiodic acid
CA3205756A1 (fr) * 2021-01-20 2022-07-28 Entasis Therapeutics Limited Compositions d'antibiotiques a dose fixe
CN113979981B (zh) * 2021-10-22 2023-04-07 天津医科大学 一种巯基响应型脱碱基位点捕获试剂及应用
WO2023206580A1 (fr) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Formes cristallines de durlobactam
CN118271319B (zh) * 2022-12-30 2025-02-28 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
WO2024227071A1 (fr) 2023-04-26 2024-10-31 Entasis Therapeutics Limited Synthèse de durlobactam
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法
WO2025031214A1 (fr) 2023-08-08 2025-02-13 成都四面体药物研究有限公司 INHIBITEUR DE β-LACTAMASE TRICYCLIQUE CONTENANT DE L'URÉE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
WO2025106662A1 (fr) 2023-11-15 2025-05-22 Entasis Therapeutics, Inc. Préparation d'intermédiaires d'acide boronique utiles dans la préparation de composés pour le traitement d'infections bactériennes
WO2025239896A1 (fr) 2024-05-16 2025-11-20 Entasis Therapeutics, Inc. Traitement de pneumonie bactérienne nosocomiale et pneumonie bactérienne acquise sous ventilation mécanique provoquée par des isolats sensibles de complexe acinetobacter baumannii-calcoaceticus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT74682A (en) * 1993-12-29 1997-01-28 Pfizer Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (fr) * 2008-06-19 2015-09-23 Astra Zeneca Holding France Utilisation de (1r, 2s, 5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy) -, sel monosodique en tant que réactif de diagnostic pour la détection de sérines bêta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2578370C2 (ru) 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
MX340533B (es) 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
EP3052497B1 (fr) 2011-09-13 2017-06-28 Wockhardt Limited Composés contenant de l'azote et leur utilisation
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
KR20150003777A (ko) 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
BR112015003592B1 (pt) 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2014141132A1 (fr) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. Nouveaux composés hétérocycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase

Also Published As

Publication number Publication date
ME03031B (fr) 2018-10-20
US20160175290A1 (en) 2016-06-23
HUE036722T2 (hu) 2018-07-30
LT2834239T (lt) 2018-03-26
AR090539A1 (es) 2014-11-19
TW201345907A (zh) 2013-11-16
CA2866467A1 (fr) 2013-10-10
EP2834239A1 (fr) 2015-02-11
CN104364254A (zh) 2015-02-18
UY34723A (es) 2015-07-31
US20150073011A1 (en) 2015-03-12
US9309245B2 (en) 2016-04-12
SG11201405965RA (en) 2014-10-30
IN2014MN01882A (fr) 2015-07-10
CN104364254B (zh) 2017-02-22
BR112014024279B1 (pt) 2021-09-08
PT2834239T (pt) 2018-03-23
MX354627B (es) 2018-03-14
MY176969A (en) 2020-08-28
IL234660A (en) 2017-08-31
BR112014024279A2 (fr) 2017-06-20
HRP20180450T1 (hr) 2018-06-01
EP2834239B1 (fr) 2017-12-27
CO7071137A2 (es) 2014-09-30
CY1120269T1 (el) 2019-07-10
TN2014000417A1 (en) 2016-03-30
AU2013245399A1 (en) 2014-10-02
NZ630259A (en) 2016-06-24
AU2013245399B2 (en) 2016-04-21
NO2935238T3 (fr) 2018-05-26
BR112014024279A8 (pt) 2018-04-03
CA2866467C (fr) 2020-03-24
JP6122484B2 (ja) 2017-04-26
JP2015512440A (ja) 2015-04-27
RS56966B1 (sr) 2018-05-31
TWI597281B (zh) 2017-09-01
ES2663416T3 (es) 2018-04-12
KR20140140625A (ko) 2014-12-09
RU2014141579A (ru) 2016-05-27
DK2834239T3 (en) 2018-03-26
AP2014007980A0 (en) 2014-10-31
MX2014011351A (es) 2014-12-05
SMT201800142T1 (it) 2018-05-02
PE20142403A1 (es) 2015-01-23
PH12014502224A1 (en) 2015-01-12
PL2834239T3 (pl) 2018-06-29
RU2645678C2 (ru) 2018-02-27
US9623014B2 (en) 2017-04-18
PH12014502224B1 (en) 2017-11-08
HK1207071A1 (en) 2016-01-22
KR102042867B1 (ko) 2019-11-08
WO2013150296A1 (fr) 2013-10-10
SI2834239T1 (en) 2018-05-31
CL2014002589A1 (es) 2015-01-30
CR20140428A (es) 2015-01-12
DOP2014000212A (es) 2014-10-31

Similar Documents

Publication Publication Date Title
MA37383A1 (fr) Compose heterobicycliques comme inhibiteurs de la beta lactamase
MA54327B1 (fr) Inhibiteurs de kras g12c
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
PH12019500558B1 (en) Beta-lactamase inhibitor compounds
MA42244A (fr) Dérivés de 3-tétrazolyl-benzène-1,2-disulfonamide en tant qu'inhibiteurs de métallo-bêta-lactamase
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA32025B1 (fr) Inhibiteurs des beta-lactamases
MA42292B1 (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA33240B1 (fr) Inhibiteurs de bêta-sécrétase
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
MA39777B1 (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
NZ626951A (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
NZ746906A (en) Oxaborole esters and uses thereof
MA46356B1 (fr) Inhibiteurs de bêta-lactamases
MA38354B1 (fr) Préparation contenant un composé de benzothiazolone
EA202190617A2 (ru) Соединения-ингибиторы бета-лактамаз